Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030-4009, USA.
Breast J. 2013 Jul-Aug;19(4):431-4. doi: 10.1111/tbj.12141. Epub 2013 May 23.
The aim of this study was to evaluate the association of bone mineral density (BMD) at the time of diagnosis with clinical-pathologic findings in patients with operable postmenopausal breast cancer. One hundred and fifty-eight postmenopausal women who had a baseline lumbar and hip BMD measurement were included in the analysis. Patients were divided into two groups based on the median BMD. p ≤ 0.002 was considered to be statistically significant. Hormone replacement therapy (HRT) use longer than 5 years was associated with increased lumbar BMD compared with patients who used HRT less than 5 years (p = 0.002). Patients with higher BMD tended to have low grade disease, no lympho-vascular invasion, progesterone receptor-positive tumors, and low Ki-67 levels (p < 0.05). Higher baseline BMD in postmenopausal patients with breast cancer is associated with favorable prognostic features.
本研究旨在评估绝经后可手术乳腺癌患者诊断时的骨密度（BMD）与临床病理特征的相关性。本分析纳入了 158 例绝经后基线腰椎和髋部 BMD 测量的女性患者。根据 BMD 的中位数将患者分为两组。p≤0.002 被认为具有统计学意义。与 HRT 使用少于 5 年的患者相比，HRT 使用超过 5 年的患者腰椎 BMD 更高（p=0.002）。BMD 较高的患者往往疾病分级较低，无淋巴管血管侵犯，孕激素受体阳性肿瘤和低 Ki-67 水平（p<0.05）。绝经后乳腺癌患者的基线 BMD 较高与预后良好的特征相关。
